| 基石药业 (2616 HK) - 下一代肿瘤免疫：CS2009三抗有望突出重围 | 陈铸鸿,谭震,陈泓道 | 2026-04-02 |
| CStone Pharmaceuticals (2616 HK) - Next-Generation Immuno-Oncology: CS2009 Trispecific Antibody Poised to Stand Out | Chen Zhuhong, Jonah,Tan Zhen,Chen Hongdao, George | 2026-04-02 |
| 优必选(9880 HK) - 业绩超预期，人形机器人将进入规模化交付阶段 | 梁勇活,殷浩程 | 2026-04-02 |
| UBTECH (9880 HK) - Better-than-expected results positions humanoid robots for large-scale delivery | Liang Yonghuo,Harrison, Yin Haocheng | 2026-04-02 |
| China Internet Sector - 4Q25 Review: Expectation reset, diverging AI narratives, long-term value recovery | Li Yishan, Crystal,Wong Tang Kit, Tommy,Zhang Henan | 2026-04-02 |
| 中国互联网行业 - 四季度业绩回顾：预期重置、AI叙事分化、长期价值回归 | 李怡珊,王腾杰,张贺楠 | 2026-04-02 |
| Geely (175 HK, BUY) - March sales review: premiumization and overseas expansion to drive high-quality growth | Liang Yonghuo,Harrison, Yin Haocheng | 2026-04-02 |
| 招商证券（国际）早会纪要 20260402 | 招商香港研究部 | 2026-04-02 |
| 迈瑞医疗 (300760 CH) - 业绩拐点已至，2026年内外双线复苏可期 | 谭震,陈铸鸿,陈泓道 | 2026-04-01 |
| Mindray Medical (300760 CH) - Inflection point has arrived; domestic & international recovery expected in 2026 | Tan Zhen,Chen Zhuhong, Jonah,Chen Hongdao, George | 2026-04-01 |
| 极智嘉（2590 HK）- 业绩符合预期，具身智能和全球化深入巩固龙头优势 | 梁勇活,殷浩程 | 2026-04-01 |
| Geek+ (2590 HK) - Earnings in line; embodied intelligence and globalization reinforce leadership | Liang Yonghuo,Harrison, Yin Haocheng | 2026-04-01 |
| Zhipu (2513 HK, NR) - Deepening model development to strengthen competitiveness | Li Yishan, Crystal,Wong Tang Kit, Tommy,Zhang Henan | 2026-04-01 |
| 招商证券（国际）早会纪要 20260401 | 招商香港研究部 | 2026-04-01 |
| 中升控股 (881 HK) - 一次性计提减值拖累业绩，售后与新能源促增长 | 梁勇活,殷浩程 | 2026-03-31 |
| Zhongsheng Group (881 HK) - One-off impairment weighed on earnings, aftermarkets and NEV to fuel growth | Liang Yonghuo,Harrison, Yin Haocheng | 2026-03-31 |
| 九毛九 (9922 HK) - 复苏进行中 | 黄铭谦 | 2026-03-31 |
| Jiumaojiu International (9922 HK) - Recovery Underway | Wong Ming Him, Joseph | 2026-03-31 |
| 赤子城科技 (9911 HK) - 全球化扩张驱动稳健增长 | 李怡珊,王腾杰,张贺楠 | 2026-03-31 |
| 翰森制药 (3692 HK) - 长期战略和最优执行，夯实稳健增长 | 陈铸鸿,谭震,陈泓道 | 2026-03-31 |